Literature DB >> 9264386

The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma.

R D Brown1, E Yuen, M Nelson, J Gibson, D Joshua.   

Abstract

Clonal T cell populations with idiotype specificity are present in the peripheral blood of a proportion of patients with multiple myeloma. We have identified the presence of both T cell subpopulations with a specificity for autologous immunoglobin fragments and T cell receptor beta gene rearrangements in peripheral blood samples of patients with myeloma. T cell receptor beta gene rearrangements were detected in 38 of 119 patient samples (32%) and were more common in progressive disease (70%), than at diagnosis (25%) or in stable disease (23%). The 38 patients who had T cell receptor beta gene rearrangements detected at any time had a better overall survival (median not yet achieved) than the patients who never had rearrangements detected (median 45 months, n = 49; chi2 = 6.2, P < 0.01). All 12 patients with T cell receptor beta gene rearrangements at diagnosis are still alive whereas the median survival for 28 patients with a germline configuration at diagnosis was 40 months (chi2 = 5.8, P > 0.01). The presence of T cell receptor beta gene rearrangements even conferred a survival advantage during progressive disease (median survival 44 months vs 19 months; chi2 = 8.7, P < 0.003). Two colour flow cytometry with biotinylated autologous immunoglobulin fragments demonstrated idiotype-reactive T cells in the peripheral blood of five out of 15 patients all of whom had T cell gene rearrangements. The remaining 10 patients had neither idiotype-reactive T cells nor a detectable T cell receptor beta gene rearrangement in concurrent samples. Thus in patients with myeloma there was a good correlation between the presence of T cell receptor beta gene rearrangements and idiotype-reactive T cells. Patients with a rearranged T cell receptor beta gene had a significantly better prognosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264386     DOI: 10.1038/sj.leu.2400714

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Authors:  H Suen; R Brown; S Yang; C Weatherburn; P J Ho; N Woodland; N Nassif; P Barbaro; C Bryant; D Hart; J Gibson; D Joshua
Journal:  Leukemia       Date:  2016-04-22       Impact factor: 11.528

3.  Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Authors:  A Barber; K R Meehan; C L Sentman
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

Review 4.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

Review 5.  The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.

Authors:  T Dosani; M Carlsten; I Maric; O Landgren
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

6.  Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.

Authors:  D J Kowalewski; S Walz; L Backert; H Schuster; O Kohlbacher; K Weisel; S M Rittig; L Kanz; H R Salih; H-G Rammensee; S Stevanović; J S Stickel
Journal:  Blood Cancer J       Date:  2016-04-08       Impact factor: 11.037

7.  Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments.

Authors:  Oliver C Goodyear; Sarah Essex; Anandram Seetharam; Supratik Basu; Paul Moss; Guy Pratt
Journal:  Oncotarget       Date:  2017-05-02

Review 8.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

9.  Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.

Authors:  C Bryant; H Suen; R Brown; S Yang; J Favaloro; E Aklilu; J Gibson; P J Ho; H Iland; P Fromm; N Woodland; N Nassif; D Hart; D E Joshua
Journal:  Blood Cancer J       Date:  2013-09-13       Impact factor: 11.037

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.